Cite
HARVARD Citation
Weisel, K. et al. (2020). Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials. Leukemia & lymphoma. 61 (1), pp. 37-46. [Online].